• Written informed consent obtained.

• Age ≥ 18 years at the time of study entry.

• Participants must have unresectable or metastatic histologically or cytologically confirmed intrahepatic cholangiocarcinoma

• Participants must have failed 1 line of systemic regimens for advanced cholangiocarcinoma due to disease progression or toxicity.

• At least one measurable site of disease as defined by RECIST1.1 criteria with spiral CT scan or MRI.

• Performance status (PS) ≤ 2 (ECOG scale).

• Life expectancy of at least 12 weeks.

• Adequate blood count, liver-enzymes, and renal function: absolute neutrophil count ≥ 1,500/L, platelets ≥75 x103/L; Total bilirubin ≤ 3x upper normal limit; Aspartate Aminotransferase (SGOT), Alanine aminotransferase (SGPT) ≤ 5 x upper normal limit (ULN); International normalized ratio (INR) ≤1.25; Albumin ≥ 31 g/dL; Serum Creatinine ≤ 1.5 x institutional ULN or creatinine clearance (CrCl) ≥ 30 mL/min (if using the Cockcroft-Gault formula)

• Female patients with reproductive potential must have a negative urine or serum pregnancy test within 7 days prior to start of trial.

• Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment, adherence to contraceptive measures, scheduled visits, and examinations including follow-up.